Boston Scientific earnings on deck as EP, Watchman doubts swirl

BSX is being priced like a near-term growth breakage story, but the market may be conflating a one-quarter digestion period with a multi-year deceleration. The bigger second-order risk is not just EPS or guide cuts; it’s multiple compression in any med-tech name whose premium is justified by “durable share gain” rather than visible end-market acceleration. If management signals that 2026 growth is still intact but merely back-half weighted, the stock can stabilize quickly because the current setup already embeds a lot of bad news and forced de-risking.

The competitive dynamic matters more than the headline clinical debate. In EP, a weaker BSX print would likely shift purchasing leverage toward rivals in hospital systems that were waiting for evidence of execution slippage, and that can spill into contract timing for the next two quarters. The more subtle effect is on capital allocation across med-device peers: a cleaner BSX reset would likely pull the sector’s “quality growth” discount down, while a guide cut would punish other high-multiple device names with similar premium narratives even if their fundamentals are fine.

The contrarian view is that the selloff may already reflect a worst-case interpretation of Watchman and EP, while physician adoption often responds with a lag after mixed data rather than a cliff. If procedure growth merely normalizes to low-double digits instead of reaccelerating, the stock can still re-rate higher from current levels because expectations have been reset sharply. The near-term catalyst window is this print plus the next 2-6 weeks of sell-side note revisions; the longer-term catalyst is whether management can credibly defend 2026 growth without leaning on overly aggressive assumptions.